WHO/Europeಪರಿಶೀಲಿಸಿದ ಖಾತೆ

.@WHO Global Advisory Committee on Vaccine Safety will continue its review of the evidence and report its conclusions tomorrow (3/3)

Following preliminary review of signal of blood clots in people vaccinated with #COVID19 vaccine AstraZeneca @EMA_News concluded the benefits in protecting people from COVID-19 with its associated risks of death and hospitalisation outweigh the risk of side effects (2/3)

This is a concrete step towards making health a centerpiece of society, preparing for future health emergencies, and making sure that the notion of health as peripheral, is a thing of the past. Stay safe. Thank you. @hans_kluge

to fix the fractures and address the conditions that allowed #COVID19 to happen @hans_kluge

Meanwhile, we have one eye fixed on the future. This week, the Pan European Commission on Health and Sustainable Development, chaired by Professor Mario Monti, issued a Call to Action - to rethink policy priorities in the light of pandemics...

#VaccinesWork, and will eventually allow a return to a new normal. But for that to happen, we need to rely on science and have confidence in the incredible protection afforded by vaccines against all vaccine-preventable diseases, including #COVID19 @hans_kluge

At this point in time, however, the benefits of the Astra Zeneca vaccine far outweigh its risks – and its use should continue, to save lives @hans_kluge

As of now, we do not know whether some or all of the conditions have been caused by the vaccine or by other coincidental factors. @WHO is assessing the latest safety data, and once completed, the findings will be made public @hans_kluge

Venous thromboembolism is the third most common cardiovascular disease in the world. It happens in populations regardless of whether they are vaccinated or not. #COVID19 vaccination will not reduce illness or deaths from other causes @hans_kluge

In vaccination campaigns, it is routine to signal potential adverse events. This does not necessarily mean that the events are linked to the vaccination @hans_kluge

The detection, investigation and assessment of these cases is a testimony to strong surveillance and regulatory mechanisms @hans_kluge

A number of countries in the Region have temporarily suspended use of the AstraZeneca vaccine as a precautionary measure based on reports from few countries of rare blood coagulation disorders in persons who had received the vaccine @hans_kluge

The WHO Regional Office for Europe & @ECDC_EU have developed a robust protocol to study vaccine effectiveness in community settings to allow effective comparison of the results between countries @hans_kluge

We welcome these studies, stressing that the available data is limited – and that further research is urgently needed @hans_kluge

As vaccine uptake increases, their broader impact will become visible, and studies like these, will guide policy and improve our understanding of how the different vaccines contribute to our response @hans_kluge

... nonetheless, early data from Israel, Scotland and the UK, linked to effectiveness against severe disease by the Pfizer/BioNTech and Astra Zeneca vaccines, is promising and show lives are being saved @hans_kluge

With vaccination coverage in the Region ranging from less than 1% to 44%, it is also far too early to demonstrate the effect of vaccines on overall #COVID19 hospitalization and deaths...